Point72 DIFC Ltd Grows Position in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)

Point72 DIFC Ltd raised its stake in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) by 598.2% during the 2nd quarter, Holdings Channel.com reports. The fund owned 66,564 shares of the biotechnology company’s stock after acquiring an additional 57,030 shares during the period. Point72 DIFC Ltd’s holdings in BioCryst Pharmaceuticals were worth $411,000 as of its most recent SEC filing.

Other hedge funds have also recently bought and sold shares of the company. CWM LLC grew its holdings in shares of BioCryst Pharmaceuticals by 200.0% in the second quarter. CWM LLC now owns 5,658 shares of the biotechnology company’s stock valued at $35,000 after acquiring an additional 3,772 shares in the last quarter. Signaturefd LLC boosted its position in BioCryst Pharmaceuticals by 560.5% in the second quarter. Signaturefd LLC now owns 6,598 shares of the biotechnology company’s stock worth $41,000 after purchasing an additional 5,599 shares during the last quarter. Quarry LP bought a new position in BioCryst Pharmaceuticals in the 4th quarter valued at $54,000. nVerses Capital LLC purchased a new stake in shares of BioCryst Pharmaceuticals during the 2nd quarter valued at $63,000. Finally, Seven Eight Capital LP bought a new stake in shares of BioCryst Pharmaceuticals during the 1st quarter worth $57,000. 85.88% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

BCRX has been the subject of several research reports. Barclays increased their price target on shares of BioCryst Pharmaceuticals from $6.00 to $7.00 and gave the company an “equal weight” rating in a research report on Tuesday, August 6th. HC Wainwright restated a “buy” rating and set a $30.00 price target on shares of BioCryst Pharmaceuticals in a research note on Tuesday, August 6th. Royal Bank of Canada reiterated an “outperform” rating and issued a $10.00 price objective on shares of BioCryst Pharmaceuticals in a research note on Tuesday, August 6th. StockNews.com raised BioCryst Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Tuesday, August 6th. Finally, JMP Securities upped their price target on BioCryst Pharmaceuticals from $15.00 to $16.00 and gave the company a “market outperform” rating in a research report on Tuesday, August 6th. One equities research analyst has rated the stock with a hold rating and six have issued a buy rating to the stock. Based on data from MarketBeat, BioCryst Pharmaceuticals has a consensus rating of “Moderate Buy” and an average target price of $14.17.

BioCryst Pharmaceuticals Price Performance

NASDAQ:BCRX opened at $7.58 on Friday. The company has a market cap of $1.56 billion, a P/E ratio of -7.08 and a beta of 1.88. BioCryst Pharmaceuticals, Inc. has a 1 year low of $4.03 and a 1 year high of $8.88. The stock’s fifty day moving average price is $7.82 and its two-hundred day moving average price is $6.41.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last issued its earnings results on Monday, August 5th. The biotechnology company reported ($0.06) EPS for the quarter, topping the consensus estimate of ($0.17) by $0.11. The company had revenue of $109.30 million during the quarter, compared to the consensus estimate of $98.30 million. During the same quarter in the prior year, the business earned ($0.24) EPS. The firm’s revenue for the quarter was up 34.9% compared to the same quarter last year. On average, analysts expect that BioCryst Pharmaceuticals, Inc. will post -0.38 earnings per share for the current fiscal year.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.